[1] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
[2] |
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nat Med, 2015, 21(11): 1350-1356.
|
[3] |
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis[J]. J Clin Oncol, 2005, 23(3): 609-618.
|
[4] |
Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage Ⅲ colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 Trial[J]. JAMA Oncol, 2016, 2(5): 643-653.
|
[5] |
Overman MJ, Ernstoff MS, Morse MA. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 239-247.
|
[6] |
Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data[J]. J Clin Oncol, 2010, 28(2): 264-271.
|
[7] |
Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study[J]. Lancet, 2007, 370(9604): 2020-2029.
|
[8] |
Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(8): 892-910.
|
[9] |
Taieb J, Svrcek M, Cohen R, et al. Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment[J]. Eur J Cancer, 2022, 175: 136-157.
|
[10] |
Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J]. J Natl Cancer Inst, 2011, 103(11): 863-875.
|
[11] |
Zhang X, Wu T, Cai X, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities[J]. Front Immunol, 2022, 13: 795972.
|
[12] |
Zheng J, Huang B, Nie X, et al. The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel[J]. Future Oncol, 2018, 14(14): 1355-1364.
|
[13] |
Mei WJ, Mi M, Qian J, et al. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: a narrative review[J]. Front Immunol, 2022, 13: 1019582.
|
[14] |
Li J, Xu Q, Luo C, et al. Clinicopathologic characteristics of resectable colorectal cancer with mismatch repair protein defects in Chinese population: Retrospective case series and literature review[J]. Medicine (Baltimore), 2020, 99(24): e20554.
|
[15] |
Liang Y, Cai X, Zheng X, et al. Analysis of the clinicopathological characteristics of stage I~III colorectal cancer patients deficient in mismatch repair proteins[J]. Onco Targets Ther, 2021, 14: 2203-2212.
|
[16] |
Lizardo DY, Kuang C, Hao S, et al. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2): 188447.
|
[17] |
Guan X, Cheng P, Wei R, et al. Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer[J]. Br J Cancer, 2024, 130(1): 31-42.
|
[18] |
Han K, Tang JH, Liao LE, et al. Neoadjuvant immune checkpoint inhibition improves organ preservation in T4bM0 colorectal cancer with mismatch repair deficiency: a retrospective observational study[J]. Dis Colon Rectum, 2023, 66(10): e996-e1005.
|
[19] |
Sacdalan DL, Garcia RL, Diwa MH, et al. Clinicopathologic factors associated with mismatch repair status among filipino patients with young-onset colorectal cancer[J]. Cancer Manag Res, 2021, 13: 2105-2115.
|
[20] |
Märkl B, Rößle J, Arnholdt HM, et al. The clinical significance of lymph node size in colon cancer[J]. Mod Pathol, 2012, 25(10): 1413-1422.
|
[21] |
Ruisch JE, Kloft M, Fazzi GE, et al. Large negative lymph nodes - a surrogate for immune activation in rectal cancer patients?[J]. Pathol Res Pract, 2020, 216(9): 153106.
|
[22] |
Märkl B, Schaller T, Kokot Y, et al. Lymph node size as a simple prognostic factor in node negative colon cancer and an alternative thesis to stage migration[J]. Am J Surg, 2016, 212(4): 775-780.
|
[23] |
Wright FC, Law CH, Last L, et al. Lymph node retrieval and assessment in stage II colorectal cancer: a population-based study[J]. Ann Surg Oncol, 2003, 10(8): 903-909.
|